Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC

June 15th 2020

In our exclusive interview, Suresh S. Ramalingam, MD, discusses the FDA approval of nivolumab plus ipilimumab for the first-line treatment of patients with metastatic non–small cell lung cancer.

Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer

June 11th 2020

In our exclusive interview, Dr. Gradishar shares the path that led him to specialize in the field of breast cancer, collective experiences that have inspired him throughout his career, and his hope for the continued transition from “shotgun medicine” to precision medicine in the field.

Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma

June 9th 2020

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma

June 8th 2020

Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma

June 4th 2020

In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.

Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era

June 2nd 2020

Mudit Chowdhary, MD, shares advice for family members living with patients with cancer, projects the long-term implications of the COVID-19 pandemic on clinical practice, provides insight on the effects of investigational treatments for patients with COVID-19, and details the protocols Rush University Medical Center has put into place to limit the spread of the virus.

Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology

May 28th 2020

In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.

Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives

May 25th 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.

FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma

May 21st 2020

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma

May 21st 2020

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

McGregor Details GU Treatment Guidelines During COVID-19 Pandemic

May 18th 2020

Bradley McGregor, MD, discusses the purpose of the guidelines, some of the main factors that influenced the recommendations in genitourinary cancers, and the impact of the pandemic on some of the most common treatment interventions such as immunotherapy, chemotherapy, and hormonal therapy, for patients with these malignancies.

FDA Approval Insights: Olaparib/Bevacizumab in HRD+ Advanced Ovarian Cancer

May 14th 2020

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer.

FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer

May 14th 2020

Talking Tumors: Exploring Management Strategies in Multiple Myeloma

May 11th 2020

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

Talking Tumors: Exploring Management Strategies in Multiple Myeloma

May 11th 2020

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

Making Headway in GI Malignancies in Miami

May 7th 2020

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

The Uromigos Unveil Updates and Insights on the Impact of COVID-19 on GU Cancers

May 4th 2020

In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.

Marvels in Medicine: Dr. Gabriel Hortobagyi on Challenging Historical Dogmas in Breast Cancer

April 30th 2020

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

FDA Approval Insights: Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

April 27th 2020

In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.

Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio

April 23rd 2020

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.